CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Zacks Investment Research7/7/2026Neutral
CRSP
Crispr Therapeutics AGNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.79B
P/E Ratio
—
EPS
$-6.17
Beta
1.70
52W High
$78.48
52W Low
$44.12
50-Day MA
$52.95
200-Day MA
$55.58
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.36
PEG Ratio
-0.21
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $4.10M |
| Gross Profit (TTM) | $-478.71M |
| EBITDA | $-531.08M |
| Operating Margin | -8933.00% |
| Return on Equity | -31.20% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $18.83 |
| Price-to-Book | 3.26 |
| Price-to-Sales (TTM) | 1411.37 |
| EV/Revenue | 4262.78 |
| EV/EBITDA | 14.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 68.60% |
| Shares Outstanding | $98.48M |
| Float | $96.03M |
| % Insiders | 5.91% |
| % Institutions | 79.26% |
Historical Volatility
HV 10-Day
51.69%
HV 20-Day
45.17%
HV 30-Day
58.90%
HV 60-Day
60.23%
HV Rank
36.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($84.70 target)
5
Strong Buy10
Buy10
HoldLatest News
Progress Report: How Our Top Stock Picks of 2026 Are Faring
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
Schaeffers Research7/7/2026Neutral
Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment
Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.
Seeking Alpha7/3/2026Positive
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research6/30/2026Positive
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Forbes6/17/2026Neutral
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research6/16/2026Positive
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha6/9/2026Neutral
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Seeking Alpha6/4/2026Neutral
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha6/4/2026Neutral
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research6/3/2026Negative
More HEALTHCARE Stocks
Data last updated: 7/9/2026